SSY GROUP(02005.HK): Bumetanide API Approved by NMPA
NewTimeSpace: SSY Group Limited(02005.HK) announced that its Bumetanide has been approved by the National Medical Products Administration (NMPA) of China for registration as an active pharmaceutical ingredient (API) for use in marketed finished products.Bumetanide is a loop diuretic, mainly indicated for the treatment of edema associated with heart failure, renal dysfunction and hepatic dysfunction.
NewTimeSpace: SSY Group Limited (02005.HK) issued a voluntary announcement on March 16, stating that its Bumetanide has been approved by the NMPA for registration as an active pharmaceutical ingredient (API) for use in marketed finished products.
Bumetanide is a loop diuretic. It is mainly used for the treatment of edema associated with heart failure, renal and hepatic dysfunction.
It is also applied in the prevention of acute renal failure, and the treatment of hypertension, hyperkalemia, hypercalcemia, dilutional hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, as well as acute drug and toxic poisoning.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- SSY Group Limited (02005.HK): Calcium Levofolinate for Injection Approved, Deemed to Have Passed Consistency Evaluation
- SSY Group Limited (02005.HK): Obtains Drug Production Registration Approval for Doxapram Hydrochloride Injection, First Approved in China
- SSY Group(02005.HK): Two APIs Approved by NMPA for Marketing
- SSY Group (02005.HK): Secures Production Registration Approval for New 2ml Specification of Potassium Dihydrogen Phosphate Complex Injection
- SSY Group (02005.HK): Sodium Glycerophosphate Injection Obtains NMPA Drug Production Registration Approval
